Isis Pharmaceuticals Up on Q4 Earnings and Revenues Beat - Analyst Blog2 Mar 2015, 8:40 amIsis Pharmaceuticals (ISIS) reported fourth-quarter 2014 earnings of 25 cents per share, easily beating the Zacks Consensus Estimate of 12 cents per share.
EXFO Reduces Testing Time by a Minimum of 50% with Release of New Loopback Fiber-Characterization Feature2 Mar 2015, 1:00 amEXFO Reduces Testing Time by a Minimum of 50% with Release of New Loopback Fiber-Characterization Feature
Here Are Five Reasons Why You Need To Buy A Mazda MX-6 Right Now27 Feb 2015, 1:53 pmA few decades ago, Mazda took chances. From its iconic RX-7 with its witchcraft-spec Rotary engine, to its physics-defying Miata, Mazda was the automaker to go to if quirk was indeed your bag. However, there was another, less well-known option that made Mazda a bona fide triple threat - the amazing Mazda MX-6. Here are a few reasons why you need to buy one right this second. Read more...
Zacks Rank #1 Additions for Tuesday - Tale of the Tape24 Feb 2015, 7:30 amHere are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Zacks Rank #1 Additions for Wednesday - Tale of the Tape11 Feb 2015, 7:30 amHere are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
EPIC Begins Selling AcuFAB Products With the Establishment of Its Product and Distribution Company11 Feb 2015, 7:00 amEPIC Corporation Inc. and Ronald Tucker its CEO announced "EPIC has established RX Healthcare Systems, Ltd., a majority owned subsidiary, as its sales and distribution company with the initiation ...
Model N Announces First Quarter Fiscal Year 2015 Financial Results9 Feb 2015, 2:05 pmModel N, Inc., , the leader in Revenue Management Cloud solutions to the life science and technology industries, today announced financial results for the first quarter
Perrigo Company plc (PRGO): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report6 Feb 2015, 5:00 amPerrigo Company's second-quarter fiscal 2015 earnings of $1.82 per share beat the Zacks Consensus Estimate of $1.78. Net sales in the quarter increased 9% to $1.1 billion in line with the Zacks Consensus Estimate
Perrigo Beats on Earnings, FY15 Guidance In Line - Analyst Blog5 Feb 2015, 8:15 amPerrigo reported second quarter fiscal 2015 earnings of $1.82 per share.
BioSyent Pharma Announces the Canadian Launch of the First of 3 New Products Using the Patented Aguettant System(R)3 Feb 2015, 6:00 amBioSyent Inc. today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of the Aguettant System for pre-filled syringes , a new urgent care product for use in hospitals ...